4.40 USD
▲+0.04+5.52%
盘后 4.23 +1.44%
2026-08-03
市值
$284.67M
市盈率
—
EPS
-1.06
股息率
—
52 周区间
2.90 – 10.08
成交量
764.70K
Beta
0.37
目标价
18.86
52W 低 2.9052W 高 10.08
价格走势
公司简介
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica...